BEThe U.S. Trade Representative, Jamieson Greer, has informed several countries—including France—that they could face trade investigations similar to the one launched against Germany regarding pharmaceutical pricing practices. The U.S. initiated a Section 301 investigation into Germany's drug pricing policies under the Trade Act of 1974, granting the president authority to impose tariffs on unfair trade practices. Discussions are ongoing between the U.S. and these countries to find alternatives to potential investigations. The U.S. has already secured commitments from the United Kingdom to increase pharmaceutical spending and reduce rebates from drug manufacturers. European nations have expressed concern that U.S. actions on drug pricing might disrupt the recently signed U.S.-EU trade deal, which limits tariffs on EU goods to 15%. Talks with Germany and other countries are described as challenging but ongoing.
Bias read (Center): The article presents information from both U.S. and European perspectives without overtly favoring one side. It includes quotes from U.S. Trade Representative Jamieson Greer and mentions European concerns about the impact on the U.S.-EU trade deal, indicating balanced coverage of the situation.
